<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01024322</url>
  </required_header>
  <id_info>
    <org_study_id>CXL</org_study_id>
    <nct_id>NCT01024322</nct_id>
  </id_info>
  <brief_title>Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas</brief_title>
  <official_title>Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cxlusa</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cxlusa</source>
  <brief_summary>
    <textblock>
      To evaluate the efficacy of ultraviolet-A (UVA)-induced cross-linking of corneal collagen
      (CXL) as a method to increase the biomechanical and biochemical stability of the cornea by
      inducing additional cross-links within or between collagen fibers using UVA light and the
      photo- mediator riboflavin. The purpose of this study is to generate data for presentation at
      medical meetings and for peer-review publication
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Terminated to initiate FDA IND-cleared study protocol
  </why_stopped>
  <start_date type="Actual">October 1, 2009</start_date>
  <completion_date type="Actual">February 3, 2017</completion_date>
  <primary_completion_date type="Actual">February 3, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Increase the biomechanical and biochemical stability of the cornea by inducing additional cross-links within</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>increase the biomechanical and biochemical stability of the cornea between collagen fibers using UVA light and the photo- mediator riboflavin</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">1189</enrollment>
  <condition>Keratoconus</condition>
  <condition>Ectasia</condition>
  <condition>Degeneration</condition>
  <arm_group>
    <arm_group_label>Ciprofloxicine or Vigamox or other.</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Nonsteroidal (Acular, Voltaren Xibrom, etc)</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Steroid (FML, Pred Forte, Flarex, etc.)</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciprofloxicine or Vigamox or other.</intervention_name>
    <description>Ciprofloxicine or Vigamox or other to be used qid till epithelialized.</description>
    <arm_group_label>Ciprofloxicine or Vigamox or other.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nonsteroidal (Acular, Voltaren Xibrom, etc)</intervention_name>
    <description>Nonsteroidal (Acular, Voltaren Xibrom, etc) used up to qid for up to 5-10 days post-op</description>
    <arm_group_label>Nonsteroidal (Acular, Voltaren Xibrom, etc)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Steroid (FML, Pred Forte, Flarex, etc.)</intervention_name>
    <description>Steroid (FML, Pred Forte, Flarex, etc.) to be used qid for 8 weeks.</description>
    <arm_group_label>Steroid (FML, Pred Forte, Flarex, etc.)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Primary care clinic.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  8 years of age or older

          -  Diagnosis of keratoconus, post-LASIK ectasia, or pellucid marginal degeneration or
             forme fruste pellucid marginal degeneration.

          -  Diagnosis of FFKC

          -  History of Radial Keratotomy with fluctuating vision.

          -  Terrien's Marginal Degeneration

          -  Ability to provide written informed consent

          -  Likely to complete all study visits

          -  Minimum corneal thickness of at least 300 250 microns measured by ultrasound or
             Pentacam for all indications other than Terriens. For Terriens, the minimal corneal
             thickness should be consistent with the surgeon's best surgical judgment.

        Exclusion Criteria:

          -  Severe corneal scarring that markedly affects vision

          -  Contraindications to any study medications or their components

          -  Pregnancy or breast feeding

          -  Active Herpes Corneal Disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Trattler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Center for Excellence in Eye Care</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roy Rubinfeld, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Re: Vision</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Center for Excellence in Eye Care</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TLC Laser Eye Center</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20852</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TLC Laser Eye Center</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>October 28, 2009</study_first_submitted>
  <study_first_submitted_qc>December 1, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2009</study_first_posted>
  <last_update_submitted>October 10, 2018</last_update_submitted>
  <last_update_submitted_qc>October 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diagnosis of keratoconus, post-LASIK ectasia, FFKC, or pellucid marginal degeneration</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconus</mesh_term>
    <mesh_term>Dilatation, Pathologic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diclofenac</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone Acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

